Genmab A/S (NASDAQ:GMAB) Cut to "Hold" at Wall Street Zen

Genmab A/S (NASDAQ:GMAB - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Sunday.

Several other equities research analysts also recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $1.07 during trading hours on Friday, reaching $22.87. 1,804,584 shares of the stock were exchanged, compared to its average volume of 1,250,743. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56. The firm has a 50 day moving average of $21.34 and a 200 day moving average of $20.80. The stock has a market cap of $14.67 billion, a PE ratio of 12.99, a PEG ratio of 6.62 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. Equities research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares in the last quarter. Barclays PLC lifted its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Genmab A/S during the fourth quarter worth $60,000. Finally, Parallel Advisors LLC increased its position in shares of Genmab A/S by 377.5% in the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company's stock worth $77,000 after purchasing an additional 2,941 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.